The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...
The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.
HealthDay on MSN13d
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver CancerFor patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...
GlobalData on MSN5d
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed successMSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback